SG11201913556SA - Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same - Google Patents
Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the sameInfo
- Publication number
- SG11201913556SA SG11201913556SA SG11201913556SA SG11201913556SA SG11201913556SA SG 11201913556S A SG11201913556S A SG 11201913556SA SG 11201913556S A SG11201913556S A SG 11201913556SA SG 11201913556S A SG11201913556S A SG 11201913556SA SG 11201913556S A SG11201913556S A SG 11201913556SA
- Authority
- SG
- Singapore
- Prior art keywords
- synthesis
- preparing
- processes
- same
- protein kinase
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170096226 | 2017-07-28 | ||
| PCT/KR2018/008383 WO2019022487A1 (en) | 2017-07-28 | 2018-07-25 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR TO PROTEIN KINASE AND METHODS FOR THEIR PREPARATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201913556SA true SG11201913556SA (en) | 2020-02-27 |
Family
ID=65040643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201913556SA SG11201913556SA (en) | 2017-07-28 | 2018-07-25 | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11198684B2 (pl) |
| EP (1) | EP3658547B1 (pl) |
| JP (1) | JP7189932B2 (pl) |
| KR (1) | KR20230137282A (pl) |
| CN (1) | CN111295381A (pl) |
| AU (1) | AU2018308164B2 (pl) |
| BR (1) | BR112020001457A2 (pl) |
| CA (1) | CA3070070A1 (pl) |
| CO (1) | CO2020000371A2 (pl) |
| DK (1) | DK3658547T3 (pl) |
| EA (1) | EA038078B1 (pl) |
| ES (1) | ES2959967T3 (pl) |
| FI (1) | FI3658547T3 (pl) |
| HR (1) | HRP20231020T1 (pl) |
| HU (1) | HUE063043T2 (pl) |
| IL (1) | IL271975B (pl) |
| LT (1) | LT3658547T (pl) |
| MA (1) | MA49705A (pl) |
| NZ (1) | NZ761158A (pl) |
| PH (1) | PH12020500093A1 (pl) |
| PL (1) | PL3658547T3 (pl) |
| PT (1) | PT3658547T (pl) |
| RS (1) | RS64545B1 (pl) |
| SA (1) | SA520411115B1 (pl) |
| SG (1) | SG11201913556SA (pl) |
| SI (1) | SI3658547T1 (pl) |
| UA (1) | UA125595C2 (pl) |
| WO (1) | WO2019022487A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3658552T3 (fi) * | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
| MA49703A (fr) * | 2017-07-28 | 2021-04-21 | Yuhan Corp | Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| WO2013014448A1 (en) * | 2011-07-27 | 2013-01-31 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| US20130165472A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US8871778B2 (en) * | 2012-01-20 | 2014-10-28 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| JP6321821B2 (ja) * | 2014-04-14 | 2018-05-09 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | ２，３，４，６−４置換ベンゼン−１，５−ジアミン誘導体、その製造方法および医薬品における使用 |
| CN105461695B (zh) * | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105524068B (zh) * | 2014-09-30 | 2017-11-24 | 上海海雁医药科技有限公司 | 氮杂双环衍生物、其制法与医药上的用途 |
| BR112017007769B1 (pt) * | 2014-10-13 | 2023-10-10 | Yuhan Corporation | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| JP2019501222A (ja) * | 2016-01-07 | 2019-01-17 | シーエス ファーマテック リミテッド | Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
-
2018
- 2018-07-25 SG SG11201913556SA patent/SG11201913556SA/en unknown
- 2018-07-25 JP JP2020504208A patent/JP7189932B2/ja active Active
- 2018-07-25 NZ NZ761158A patent/NZ761158A/en not_active IP Right Cessation
- 2018-07-25 EP EP18838718.7A patent/EP3658547B1/en active Active
- 2018-07-25 DK DK18838718.7T patent/DK3658547T3/da active
- 2018-07-25 LT LTEPPCT/KR2018/008383T patent/LT3658547T/lt unknown
- 2018-07-25 US US16/633,756 patent/US11198684B2/en active Active
- 2018-07-25 ES ES18838718T patent/ES2959967T3/es active Active
- 2018-07-25 MA MA049705A patent/MA49705A/fr unknown
- 2018-07-25 UA UAA202001302A patent/UA125595C2/uk unknown
- 2018-07-25 WO PCT/KR2018/008383 patent/WO2019022487A1/en active Application Filing
- 2018-07-25 IL IL271975A patent/IL271975B/en unknown
- 2018-07-25 FI FIEP18838718.7T patent/FI3658547T3/fi active
- 2018-07-25 CN CN201880048980.9A patent/CN111295381A/zh active Pending
- 2018-07-25 BR BR112020001457-5A patent/BR112020001457A2/pt unknown
- 2018-07-25 HR HRP20231020TT patent/HRP20231020T1/hr unknown
- 2018-07-25 AU AU2018308164A patent/AU2018308164B2/en active Active
- 2018-07-25 CA CA3070070A patent/CA3070070A1/en active Pending
- 2018-07-25 RS RS20230685A patent/RS64545B1/sr unknown
- 2018-07-25 SI SI201830982T patent/SI3658547T1/sl unknown
- 2018-07-25 PT PT188387187T patent/PT3658547T/pt unknown
- 2018-07-25 PL PL18838718.7T patent/PL3658547T3/pl unknown
- 2018-07-25 HU HUE18838718A patent/HUE063043T2/hu unknown
- 2018-07-25 EA EA202090384A patent/EA038078B1/ru unknown
-
2020
- 2020-01-14 PH PH12020500093A patent/PH12020500093A1/en unknown
- 2020-01-15 CO CONC2020/0000371A patent/CO2020000371A2/es unknown
- 2020-01-22 SA SA520411115A patent/SA520411115B1/ar unknown
-
2023
- 2023-09-21 KR KR1020230126377A patent/KR20230137282A/ko not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287136A (en) | Receptor inhibitors - interacting with protein kinase 1 | |
| IL270872A (en) | Crystalline forms of an FGFR inhibitor and a process for their preparation | |
| IL271938A (en) | A method for making synthesis gas | |
| IL271939A (en) | A method for making synthesis gas | |
| IL271940A (en) | A method for preparing gas for the synthesis of ammonia | |
| IL271942B1 (en) | A process for the co-production of methanol and ammonia | |
| IL271975A (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for their preparation | |
| IL271941A (en) | A method for making synthesis gas | |
| IL271937A (en) | A method for preparing gas for the synthesis of ammonia | |
| EP3712130A4 (en) | METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF | |
| EP3376870A4 (en) | PROCESS FOR PREPARING KINASE INHIBITORS AND INTERMEDIATES THEREOF | |
| EP3611171A4 (en) | METHOD OF SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | |
| GB201801768D0 (en) | Synthesis method | |
| ZA202003590B (en) | Process for the preparation of opicapone and intermediates thereof | |
| ZA202101837B (en) | Method for the preparation of synthesis gas | |
| HUE062956T2 (hu) | Eljárások niraparib és köztitermékei elõállítására | |
| IL291221A (en) | Methods for the synthesis of wolbenzine | |
| IL276088A (en) | Sulfentrazone synthesis process | |
| PT3759082T (pt) | Processo para a síntese de 6-clorometiluracilo | |
| PT3713952T (pt) | Método para a síntese de derivados de glutationa | |
| EP3452447A4 (en) | IRES-MEDIATED PROTEIN SYNTHESIS INHIBITORS | |
| PL3609877T3 (pl) | Sposób syntezy firokoksybu | |
| GB201809404D0 (en) | Method of synthesis | |
| GB201807468D0 (en) | Methods of synthesis | |
| GB201713868D0 (en) | Chlormadinone drug intermediates o-tetrachlorobenzoquinone synthesis method |